PharmGKB contains no dosing guidelines for this gene. To report known dosing guidelines, or if you are interested in developing guidelines, click here.
PharmGKB contains no drug labels with pharmacogenomic information for this gene. To report a drug label with PGx, click here.
PharmGKB contains no clinical annotations for this gene. To report clinical variants, click here.
PharmGKB contains no genetic tests for this gene. To report genetic tests, click here.
Overview
| Alternate Names: | ELAV-like 1; ELAV-like protein 1; Embryonic lethal, abnormal vision, drosophila, homolog-like 1; Hu antigen R; embryonic lethal, abnormal vision, drosophila, homolog-like 1; hu-antigen R |
|---|---|
| Alternate Symbols: | ELAV1; HUR; HuR; Hua; MelG |
| PharmGKB Accession Id: | PA27740 |
Details
| Cytogenetic Location: | chr19 : p13.2 - p13.2 |
|---|---|
| GP mRNA Boundary†: | chr19 : 8023457 - 8070529 |
| GP Gene Boundary†: | chr19 : 8020457 - 8080529 |
| Strand: | minus |
| Product Name: | No data available |
†
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped
onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries
by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for
potential regulatory regions.
Publications related to ELAVL1: 2
|
Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer research. 2004. Denkert Carsten, et al. [Article:14729623@PubMed] |
|
|
The RNA-binding protein HuR regulates the expression of cyclooxygenase-2. The Journal of biological chemistry. 2003. Sengupta Sibani, et al. [Article:12704185@PubMed] |
LinkOuts
- UniProtKB:
- ELAV1_HUMAN (Q15717)
- Ensembl:
- ENSG00000066044
- GenAtlas:
- ELAVL1
- GeneCard:
- GC19M008023 (1994)
- MutDB:
- ELAVL1
- ALFRED:
- LO027429Y